These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21959288)

  • 21. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updating molecular properties during early drug discovery.
    Caron G; Ermondi G
    Drug Discov Today; 2017 Jun; 22(6):835-840. PubMed ID: 27890670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advancing drug discovery: a pharmaceutics perspective.
    Kwong E
    J Pharm Sci; 2015 Mar; 104(3):865-71. PubMed ID: 25482223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution.
    Henchoz Y; Bard B; Guillarme D; Carrupt PA; Veuthey JL; Martel S
    Anal Bioanal Chem; 2009 Jun; 394(3):707-29. PubMed ID: 19184676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds.
    Yang Y; Engkvist O; Llinàs A; Chen H
    J Med Chem; 2012 Apr; 55(8):3667-77. PubMed ID: 22443161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Getting physical to fix pharma.
    Connelly PR; Vuong TM; Murcko MA
    Nat Chem; 2011 Aug; 3(9):692-5. PubMed ID: 21860457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The seven types of drug discovery waste: toward a new lean for the drug industry.
    Uitdehaag JC
    Drug Discov Today; 2011 May; 16(9-10):369-71. PubMed ID: 21354473
    [No Abstract]   [Full Text] [Related]  

  • 28. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
    Roy A; McDonald PR; Sittampalam S; Chaguturu R
    Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.
    Bohnert T; Patel A; Templeton I; Chen Y; Lu C; Lai G; Leung L; Tse S; Einolf HJ; Wang YH; Sinz M; Stearns R; Walsky R; Geng W; Sudsakorn S; Moore D; He L; Wahlstrom J; Keirns J; Narayanan R; Lang D; Yang X;
    Drug Metab Dispos; 2016 Aug; 44(8):1399-423. PubMed ID: 27052879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
    Bayliss MK; Butler J; Feldman PL; Green DV; Leeson PD; Palovich MR; Taylor AJ
    Drug Discov Today; 2016 Oct; 21(10):1719-1727. PubMed ID: 27423371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wrong questions, wrong answers? Are we getting the drugs we need?
    Lipworth WL; Kerridge IH; Day RO
    Clin Pharmacol Ther; 2012 Mar; 91(3):367-9. PubMed ID: 22343808
    [No Abstract]   [Full Text] [Related]  

  • 35. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A chemogenomic analysis of ionization constants--implications for drug discovery.
    Manallack DT; Prankerd RJ; Nassta GC; Ursu O; Oprea TI; Chalmers DK
    ChemMedChem; 2013 Feb; 8(2):242-55. PubMed ID: 23303535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process.
    Lamanna C; Bellini M; Padova A; Westerberg G; Maccari L
    J Med Chem; 2008 May; 51(10):2891-7. PubMed ID: 18419111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can biochemistry drive drug discovery beyond simple potency measurements?
    Chène P
    Drug Discov Today; 2012 Apr; 17(7-8):388-95. PubMed ID: 22326379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toward in silico structure-based ADMET prediction in drug discovery.
    Moroy G; Martiny VY; Vayer P; Villoutreix BO; Miteva MA
    Drug Discov Today; 2012 Jan; 17(1-2):44-55. PubMed ID: 22056716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.